Investors
A MESSAGE FROM OUR CEO
”There are more than 400,000 newly diagnosed patients each year in the Western World of which a large fraction would benefit from treatment with resomelagon as a new effective and safe treatment option.
-
December 19, 2024 RegulatoryUpdated first day of trading in subscriptions rights
-
December 17, 2024 RegulatorySynAct Pharma AB announces outcome of the directed share issues
-
December 17, 2024 RegulatorySynAct Pharma AB publishes prospectus in connection with admission to trading of new shares on Nasdaq Stockholm
The interim report for Q3 2024 was published on October 30, 2024, at 07.30 CEST.